#COVID-19 vaccine

Approximately 1 in 3 Americans 65 and older who completed their initial vaccination round still have not received a first booster shot.

People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.

National Comprehensive Cancer Network encourages second mRNA booster shot and offers COVID PrEP advice for people with cancer.

A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.

The United States might see one of the steepest increases in the country’s uninsured rate in years.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

The quick spread of the BA.2 subvariant is likely due to its greater infectiousness rather than its ability to evade the immune system.

NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.

In which I share my experiences with the booster shot of the COVID-19 vaccine

While vaccination typically provides robust protection against severe disease, they’re less effective for immunocompromised people.

The benefits of achieving herd immunity thresholds have been less successful with respiratory viruses that continually mutate.

Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.

Immunocompromised people ages 12 and older are also eligible for an additional shot.

Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.

Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.

Some people undergoing cancer treatment do not respond well to COVID-19 vaccines, leaving them at risk for severe illness.